Provenge Nod Lifts Spirits And Stocks, But Also Sets High Bar For Success
Approval of Dendreon's Provenge is a major achievement and a shot in the arm for the growing field of therapeutic cancer vaccines, but it also serves as a reminder of the high bar for clinical and regulatory success in uncharted territory
You may also be interested in...
Hopes For Glaxo’s MAGE-A3 Vaccine Grow Dim As Trial Misses Endpoint
Glaxo’s vaccine fails co-primary endpoint in Phase III DERMA study of melanoma – trial is allowed to continue but hopes for success are not high. Top-line release raises specter that drug could become yet another failed cancer vaccine.
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot
With the potential for a multi-billion-dollar blockbuster on its hands, Eli Lilly could conduct a confirmatory trial or even seek near-term approval of sola after pooled data revealed a hint of disease modifying potential in mildly affected Alzheimer’s patients, though the company also may be grasping at straws.
With IPO Off The Table, Argos Takes $25 Million From VCs
The cancer immunotherapy developer withdrew its IPO registration last month, turning instead to insider investors as it prepares for a pivotal Phase III trial on a dendritic cell treatment.